Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CR2 |
| Gene Name: | CR2 |
| Protein Full Name: | Complement receptor type 2 |
| Alias: | C3DR; CD21; Complement C3d receptor; Complement component (3d/Epstein Barr virus) receptor 2; EBV receptor; Epstein-Barr virus receptor |
| Mass (Da): | 112974 |
| Number AA: | 1033 |
| UniProt ID: | P20023 |
| Locus ID: | 1380 |
| COSMIC ID: | CR2 |
| Gene location on chromosome: | 1q32.2 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19582 |
| Percent of cancer specimens with mutations: | 1.59 |
| Normal role description: | CR2 is a membrane protein on B and T lymphocytes to which complement C3Dd, as well as the Epstein-Barr virus binds during infection of these cells. It participates in B lymphocyte maturation. Mutations in the gene have been associated with an increased susceptibility for systemic lupus erythematosus type 9 |
| Commentary on involvement of protein in cancer: | 1 squamous cell carcinoma from the larynx was also mutated (mis-sense). Only 1 ovarian and 2 bladder samples were examined. |